RSS feed

Publications by Morten Brændengen

19 publications found

Original articles

Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C (2022)
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
ESMO Open, 7 (5), 100589
DOI 10.1016/j.esmoop.2022.100589, PubMed 36183444

Osong B, Masciocchi C, Damiani A, Bermejo I, Meldolesi E, Chiloiro G, Berbee M, Lee SH, Dekker A, Valentini V, Gerard JP, Rödel C, Bujko K, van de Velde C, Folkesson J, Sainato A, Glynne-Jones R, Ngan S, Brændengen M, Sebag-Montefiore D, van Soest J (2022)
Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery
Phys Imaging Radiat Oncol, 22, 1-7
DOI 10.1016/j.phro.2022.03.002, PubMed 35372704

Slørdahl KS, Klotz D, Olsen JÅ, Skovlund E, Undseth C, Abildgaard HL, Brændengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
Acta Oncol, 60 (7), 921-930
DOI 10.1080/0284186X.2021.1918763, PubMed 33966592

Frydenberg H, Harsem NK, Ofigsbø Å, Skoglund H, Brændengen M, Kaasa S, Guren MG (2020)
Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report
Clin Colorectal Cancer, 19 (2), 141-144
DOI 10.1016/j.clcc.2020.02.013, PubMed 32222353

Brændengen M, Glimelius B (2018)
Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers
Radiother Oncol, 127 (3), 392-395
DOI 10.1016/j.radonc.2018.05.004, PubMed 29778486

Guren MG, Kørner H, Pfeffer F, Myklebust TÅ, Eriksen MT, Edna TH, Larsen SG, Knudsen KO, Nesbakken A, Wasmuth HH, Vonen B, Hofsli E, Færden AE, Brændengen M, Dahl O, Steigen SE, Johansen MJ, Lindsetmo RO, Drolsum A, Tollåli G, Dørum LM, Møller B, Wibe A (2015)
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010
Acta Oncol, 54 (10), 1714-22
DOI 10.3109/0284186X.2015.1034876, PubMed 25924970

Braendengen M, Guren MG, Glimelius B (2013)
Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?
Curr. Colorectal Cancer Rep., 9 (2), 116-125
DOI 10.1007/s11888-013-0170-9

Radu C, Norrlid O, Brændengen M, Hansson K, Isacsson U, Glimelius B (2012)
Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients
Acta Oncol, 52 (3), 528-37
DOI 10.3109/0284186X.2012.737022, PubMed 23113591

Brændengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund Å, Brandberg Y, Glimelius B (2011)
Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study
Eur J Cancer, 48 (6), 813-9
DOI 10.1016/j.ejca.2011.06.035, PubMed 21782418

Brændengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B (2011)
Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study
Int J Radiat Oncol Biol Phys, 81 (4), e439-45
DOI 10.1016/j.ijrobp.2011.03.031, PubMed 21641122

Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund Å, Glimelius B (2010)
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study
Int J Radiat Oncol Biol Phys, 81 (4), 1017-24
DOI 10.1016/j.ijrobp.2010.07.007, PubMed 20932687

Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B (2008)
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
J Clin Oncol, 26 (22), 3687-94
DOI 10.1200/JCO.2007.15.3858, PubMed 18669453

Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O (2004)
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer
J Clin Oncol, 22 (1), 31-8
DOI 10.1200/JCO.2004.05.188, PubMed 14701765

Wiig JN, Waehre H, Larsen SG, Braendengen M, Giercksky KE (2003)
Radical prostatectomy for locally advanced primary or recurrent rectal cancer
Eur J Surg Oncol, 29 (5), 455-8
DOI 10.1016/s0748-7983(03)00030-1, PubMed 12798751

Wiig JN, Poulsen JP, Larsen S, Braendengen M, Waehre H, Giercksky KE (2002)
Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer
Eur J Surg, 168 (1), 42-8
DOI 10.1080/110241502317307562, PubMed 12022371

Braendengen M, Winderen M, Fosså SD (1996)
Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer
Br J Urol, 77 (1), 36-40
DOI 10.1046/j.1464-410x.1996.08467.x, PubMed 8653315

Review articles

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Sørbye H, Braendengen M, Balteskard L (2008)
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 194-7
PubMed 18202732

Braendengen M, Bruland OS, Olsen DR (2000)
[Radiotherapy of skeletal metastases]
Tidsskr Nor Laegeforen, 120 (16), 1870-4
PubMed 10925615